New phase 3a liraglutide 3 mg data showed weight-loss efficacy across a range of baseline BMI categories, and significant improvements in health-related quality of life…
New data from the phase 3a SCALE™ (Satiety and Clinical Adiposity−Liraglutide Evidence in Non-diabetic and Diabetic people) Obesity and Pre-diabetes trial were presented at ObesityWeek. In adults with obesity, weight loss with liraglutide 3 mg treatment, in combination with a reduced-calorie diet and physical activity, was similar across a range of baseline body mass index (BMI) subgroups from overweight to Class III obesity, at 56 weeks (P=0.054, %; P=0.54).1 Adults treated with liraglutide 3 mg who completed the 56-week trial demonstrated significantly greater weight loss of 9.2% compared with placebo (3.5%, estimated difference [ED] 5.7%, P<0.0001).1 Weight loss with liraglutide 3 mg as an adjunct to a reduced-calorie diet and physical activity was associated with improved health-related quality of life (HRQoL).2
Treatment with liraglutide 3 mg provided significantly greater weight loss of 8% from baseline compared with 2.6% with placebo (P<0.0001) at 56 weeks,2 independent of baseline BMI (≤29.9 kg/m2 [-7.5% liraglutide 3 mg vs. -0.9% placebo], 30–34.9 [-8.3% vs. -2.6%], 35–39.9 [-9.3% vs. -3.4%] and ≥40 [-7.4% vs. -2.8%], all P<0.0001).3 In addition, weight loss with liraglutide 3 mg was independent of pre-diabetes status at screening (-8.0% vs. -7.9%, P=0.59).1 All treatment groups followed a reduced-calorie diet and an increased physical activity program.1 A larger proportion of adults treated with liraglutide 3 mg completed the 56-week trial compared with those on placebo (72% vs. 64%).1
- The SCALE™ Obesity and Pre-diabetes trial is a randomized, double-blind, placebo-controlled, multinational trial in non-diabetic adults with obesity and non-diabetic adults who are overweight with comorbidities.
- The objectives of this trial were to demonstrate clinically meaningful weight loss at 56 weeks, as well as to investigate the long-term efficacy of liraglutide 3 mg to delay the onset of type 2 diabetes in participants with pre-diabetes at screening.
- Treatment with liraglutide 3 mg provided significantly greater weight loss of 9.2% from baseline.
1 Greenway F, Le Roux C, Lau D, et al. Additional analyses of the weight-lowering efficacy of liraglutide 3.0 mg in overweight and obese adults: the SCALE™ obesity and pre-diabetes, a randomized, double-blind and placebo-controlled trial. Paper presented at: Obesity Week 2014, the 2nd Annual Congress of The American Society for Metabolic and Bariatric Surgery and The Obesity Society. November 2-7,2014;Boston, MA.